Two patient deaths have been tied to the use of an implantable infusion pump that has already been mostly withdrawn from the US market over quality issues, Medtronic PLC revealed in a letter to UK physicians concerning its SynchroMed II implantable infusion pump.
The October field safety notice states that SynchroMed II pumps have a potential for over-infusion, meaning patients might get more medication than required. While an alarm on the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?